Clinical Trial: Stem Cell Ophthalmology Treatment Study
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Bone Marrow Derived Stem Cell Ophthalmology Treatment Study
Brief Summary: This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Detailed Summary: Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include degenerative, ischemic or physical damage ( examples may include macular degeneration, hereditary retinal dystrophies such as retinitis pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve conditions may include degenerative, ischemic or physical damage ( examples may include optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ). Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and intravenous. Patients will be followed for 12 months with serial comprehensive eye examinations including relevant imaging and diagnostic ophthalmic testing.
Sponsor: Retina Associates of South Florida
Current Primary Outcome: Visual acuity [ Time Frame: 1 day to 12 months ]
Original Primary Outcome: Visual acuity [ Time Frame: 1 day to 12 months ]
Current Secondary Outcome: Visual fields [ Time Frame: 1 day to 12 months ]
Original Secondary Outcome: Same as current
Information By: Retina Associates of South Florida
Dates:
Date Received: August 8, 2013
Date Started: August 2013
Date Completion: August 2017
Last Updated: December 18, 2016
Last Verified: December 2016